Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022
Letter

SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia

Cite This Article

To the Editor: We read with interest the observations by Manning et al. (1) that serum collected from malaria-infected persons in Cambodia before the coronavirus disease (COVID-19) pandemic harbored seroreactivity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigens but lacked neutralizing activity. These results suggest that malaria exposure may increase background reactivity in SARS-CoV-2 serosurveys and more specific measures of exposure, such as surrogate virus neutralization tests (sVNTs), may be necessary to capture functional SARS-CoV-2 seroreactivity in malaria-endemic areas. Additional studies in settings with distinct malaria transmission intensities would generalize and strengthen these findings.

One hypothesis for the unexpectedly moderate burden of SARS-CoV-2 in malaria-endemic countries in Africa is that exposure to Plasmodium falciparum confers functional protection against COVID-19 through cross-reactivity or general immune activation. To test this hypothesis, we analyzed 237 dried blood spot samples taken in January 2020 (prepandemic) from P. falciparum–exposed persons in a high-transmission setting in western Kenya for the presence of SARS-CoV-2 neutralizing antibodies (nAbs) using the GenScript SARS-CoV2 sVNT assay (https://www.genscript.com). Monthly P. falciparum real-time PCR results were collected in a previous study (2) for 138/237 persons in the 12 months prior to January 2020. Of these, 131 (95%) were infected with P. falciparum at least 1 time in 2019, suggesting that most persons included in this screening had been recently exposed to malaria parasites.

Consistent with findings in Manning et al. (1), none of the 237 people harbored SARS-CoV-2 nAbs, despite high prior levels of exposure to P. falciparum. Although nAbs are subject to decay after infection (3), this lack of nAb activity suggests that sVNTs offer a more specific measure of SARS-CoV-2 exposure than standard ELISAs (4). We further suggest that, given that protection from SARS-CoV-2 infection may be associated with the presence of nAbs (5), their absence in samples from both the Manning et al. study (1) and our study does not support the notion that P. falciparum infections elicit functional humoral responses against COVID-19.

Top

Acknowledgment

This work was supported by the National Institute of Allergy and Infectious Diseases (R21AI167242 to W.P.O. and S.M.T. and F32AI149950 to C.F.M.)

Top

Jillian T. Grassia, Christine F. MarkwalterComments to Author , Wendy P. O’Meara, Steve M. Taylor, and Andrew A. Obala

Top

References

  1. Manning  J, Zaidi  I, Lon  C, Rosas  LA, Park  J-K, Ponce  A, et al. SARS-CoV-2 cross-reactivity in prepandemic serum from rural malaria-infected persons, Cambodia. Emerg Infect Dis. 2022;28:4404. DOIPubMedGoogle Scholar
  2. Sumner  KM, Mangeni  JN, Obala  AA, Freedman  E, Abel  L, Meshnick  SR, et al. Impact of asymptomatic Plasmodium falciparum infection on the risk of subsequent symptomatic malaria in a longitudinal cohort in Kenya. eLife. 2021;10:e68812. DOIPubMedGoogle Scholar
  3. Chia  WN, Zhu  F, Ong  SWX, Young  BE, Fong  S-W, Le Bert  N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021;2:e2409. DOIPubMedGoogle Scholar
  4. Tan  CW, Chia  WN, Qin  X, Liu  P, Chen  MIC, Tiu  C, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38:10738. DOIPubMedGoogle Scholar
  5. Addetia  A, Crawford  KHD, Dingens  A, Zhu  H, Roychoudhury  P, Huang  M-L, et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. J Clin Microbiol. 2020;58:e0210720. DOIPubMedGoogle Scholar

Top

Cite This Article

DOI: 10.3201/eid2805.220404

Original Publication Date: April 11, 2022

Related Links

Top

Table of Contents – Volume 28, Number 5—May 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Christine Markwalter, Duke Global Health Institute, 310 Trent Dr, Durham, NC, 27707, USA

Send To

10000 character(s) remaining.

Top

Page created: March 10, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external